What is the best management strategy for patients with severe insulin resistance?

Clinical Endocrinology

Volumn 73, Issue 3, 2010, Pages 286-290

  Semple, Robert K ^a   Williams, Rachel M ^b   Dunger, David B ^b  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN;

ARTICLE; BODY WEIGHT; DIABETES MELLITUS; DISEASE SEVERITY; EARLY DIAGNOSIS; GENETIC SCREENING; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEPRECHAUNISM; LIPODYSTROPHY; METABOLIC DISORDER; NASOGASTRIC TUBE; OBESITY; PRIORITY JOURNAL; RABSON MENDENHALL SYNDROME; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES COMPLICATIONS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; HYPOGLYCEMIA; INFANT, NEWBORN; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MUTATION; POLYCYSTIC OVARY SYNDROME; RECEPTOR, INSULIN; RECOMBINANT PROTEINS; SYNDROME; TREATMENT OUTCOME;

EID: 77955744857     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03810.x     Document Type: Article

References (31)

1. Souren, N.Y., Paulussen, A.D., Loos, R.J. et al. (2007) Anthropometry, carbohydrate and lipid metabolism in the East Flanders Prospective Twin Survey: heritabilities. Diabetologia, 50, 2107 2116.
2. Eckel, R.H. (2008) Clinical practice. Nonsurgical management of obesity in adults. New England Journal of Medicine, 358, 1941 1950.
3. McGovern, L., Johnson, J.N., Paulo, R. et al. (2008) Clinical review: treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. Journal of Clinical Endocrinology and Metabolism, 93, 4600 4605.
4. Taylor, S.I. Arioglu, E. (1999) Genetically defined forms of diabetes in children. Journal of Clinical Endocrinology and Metabolism, 84, 4390 4396.
5. Musso, C., Cochran, E., Moran, S.A. et al. (2004) Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore), 83, 209 222.
6. Garg, A. (2004) Acquired and inherited lipodystrophies. New England Journal of Medicine, 350, 1220 1234.
7. Chong, A.Y., Lupsa, B.C., Cochran, E.K. et al. (2009) Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia, 53, 27 35.
8. Semple, R.K., Savage, D.B. O'Rahilly, S. (2010) Genetics of severe insulin resistance. In : J. Wass, S. Shalet eds. Oxford Textbook of Endocrinology and Diabetes. Oxford University Press, Oxford (in press).
9. D'Ercole, A.J., Underwood, L.E., Groelke, J. et al. (1979) Leprechaunism: studies of the relationship among hyperinsulinism, insulin resistance, and growth retardation. Journal of Clinical Endocrinology and Metabolism, 48, 495 502.
10. Ogilvy-Stuart, A.L., Soos, M.A., Hands, S.J. et al. (2001) Hypoglycemia and resistance to ketoacidosis in a subject without functional insulin receptors. Journal of Clinical Endocrinology and Metabolism, 86, 3319 3326.
11. http://www.cuh.org.uk/addenbrookes/services/clinical/genetics/labs/ labs-index.html.
12. Semple, R.K., Savage, D.B., Halsall, D.J. et al. (2010) Syndromes of severe insulin resistance and/or lipodystrophy. In : R.E. Weiss, S. Refetoff eds. Genetic Diagnosis of Endocrine Disorders. Elsevier, London, 39 52.
13. McDonald, A., Williams, R.M., Regan, F.M. et al. (2007) IGF-I treatment of insulin resistance. European Journal of Endocrinology, 157 (Suppl. 1 S51 S56.
14. Kuzuya, H., Matsuura, N., Sakamoto, M. et al. (1993) Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes, 42, 696 705.
15. Quin, J.D., Fisher, B.M., Paterson, K.R. et al. (1990) Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome. New England Journal of Medicine, 323, 1425 1426.
16. Schoenle, E.J., Zenobi, P.D., Torresani, T. et al. (1991) Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia, 34, 675 679.
17. Nakae, J., Kato, M., Murashita, M. et al. (1998) Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. Journal of Clinical Endocrinology and Metabolism, 83, 542 549.
18. Takahashi, Y., Kadowaki, H., Momomura, K. et al. (1997) A homozygous kinase-defective mutation in the insulin receptor gene in a patient with leprechaunism. Diabetologia, 40, 412 420.
19. Longo, N., Singh, R., Griffin, L.D. et al. (1994) Impaired growth in Rabson-Mendenhall syndrome: lack of effect of growth hormone and insulin-like growth factor-I. Journal of Clinical Endocrinology and Metabolism, 79, 799 805.
20. Vestergaard, H., Rossen, M., Urhammer, S.A. et al. (1997) Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. European Journal of Endocrinology, 136, 475 482.
21. Cochran, E., Musso, C. Gorden, P. (2005) The use of U-500 in patients with extreme insulin resistance. Diabetes Care, 28, 1240 1244.
22. Quin, J.D., Checkley, A., Gallagher, A. et al. (1994) Response of insulin-like growth factor (IGF)-binding protein-1 (IGFBP-1) and IGFBP-3 to IGF-I treatment in severe insulin resistance. Journal of Endocrinology, 141, 177 182.
23. Cochran, E., Young, J.R., Sebring, N. et al. (2004) Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. Journal of Clinical Endocrinology and Metabolism, 89, 1548 1554.
24. Kahn, C.R., Flier, J.S., Bar, R.S. et al. (1976) The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. New England Journal of Medicine, 294, 739 745.
25. Semple, R.K., Cochran, E.K., Soos, M.A. et al. (2008) Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care, 31, 977 979.
26. Semple, R.K., Soos, M.A., Luan, J. et al. (2006) Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism, 91, 3219 3223.
27. Semple, R.K., Halberg, N.H., Burling, K. et al. (2007) Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes, 56, 1712 1717.
28. Semple, R.K., Sleigh, A., Murgatroyd, P.R. et al. (2009) Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. Journal of Clinical Investigation, 119, 315 322.
29. Hattori, Y., Satoh, H., Namatame, T. et al. (2006) A patient with extreme insulin resistance syndrome treated with pioglitazone. Diabetes Care, 29, 2328 2329.
30. Vestergaard, H., Lund, S. Pedersen, O. (2001) Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism. Journal of Internal Medicine, 250, 406 414.
31. Regan, F.M., Williams, R.M., McDonald, A. et al. (2010) Treatment with recombinant human IGF-I/rhIGFBP-3 complex improves metabolic control in subjects with severe insulin resistance. Journal of Clinical Endocrinology and Metabolism, Epub ahead of print.